Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study-Reference-Cited by-同舟云学术

Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study

Published:2017-03 Issue:3 Volume:5 Page:e359-e369
ISSN:2214-109X
Container-title:The Lancet Global Health
language:en
Short-container-title:The Lancet Global Health

Author:

Cohen Cheryl,von Mollendorf Claire,de Gouveia Linda,Lengana Sarona,Meiring Susan,Quan Vanessa,Nguweneza Arthermon,Moore David P,Reubenson Gary,Moshe Mamokgethi,Madhi Shabir A,Eley Brian,Hallbauer Ute,Finlayson Heather,Varughese Sheeba,O'Brien Katherine L,Zell Elizabeth R,Klugman Keith P,Whitney Cynthia G,von Gottberg Anne

Publisher

Elsevier BV

Subject

General Medicine

Reference20 articles.

1. Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study;Mackenzie;Lancet Infect Dis,2016

2. Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in HIV-infected and -uninfected children in South Africa: a matched case-control study;Cohen;Clin Infect Dis,2014

3. Effects of vaccination on invasive pneumococcal disease in South Africa;von Gottberg;N Engl J Med,2014

4. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine;Miller;Vaccine,2011

5. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study;Andrews;Lancet Infect Dis,2014

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea;Vaccine;2024-09

2. The metabolic, virulence and antimicrobial resistance profiles of colonising Streptococcus pneumoniae shift after PCV13 introduction in urban Malawi;Nature Communications;2023-11-17

3. Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial;The Lancet Infectious Diseases;2023-05

4. Optimal age targeting for pneumococcal vaccination in older adults; a modelling study;Nature Communications;2023-02-16

5. Optimal age targeting for pneumococcal vaccination in older adults; a modelling study;2022-11-08